Sign in

CIK 0001061983

  • Large accelerated filer

CYTOKINETICS INC

Sign in to watch
Ticker
CYTK
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
943291317
Phone
+1 650-624-3000
Business address
350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$13,320,469
in 18 filings, $12.5M under 10b5-1 plans

Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-06 Malik Fady Ibraham EVP Research & Development Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −28,605 57,209
2024-01-31 Blum Robert I President & CEO Exercise or conversion 10b5-1 +12,500 $6.67 $83K 454,297
2024-01-31 Blum Robert I President & CEO Sale 10b5-1 −12,500 $79.57 $995K 441,797
2024-01-31 Blum Robert I President & CEO Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −12,500 130,994
2024-01-19 Blum Robert I President & CEO Exercise or conversion 10b5-1 +12,500 $6.67 $83K 454,297
2024-01-19 Blum Robert I President & CEO Sale 10b5-1 −12,500 $81.42 $1.0M 441,797
2024-01-19 Blum Robert I President & CEO Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −12,500 143,494
2024-01-12 HENDERSON JOHN T Director Exercise or conversion 10b5-1 +5,000 $4.44 $22K 47,632
2024-01-12 HENDERSON JOHN T Director Sale 10b5-1 −5,000 $85.14 $426K 42,632
2024-01-12 HENDERSON JOHN T Director Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 −5,000 5,000
2024-01-04 Malik Fady Ibraham EVP Research & Development Exercise or conversion 10b5-1 +11,678 $7.96 $93K 162,651
2024-01-04 Malik Fady Ibraham EVP Research & Development Sale 10b5-1 −11,678 $86.98 $1.0M 150,973
2024-01-04 Malik Fady Ibraham EVP Research & Development Sale 10b5-1 −4,000 $86.99 $348K 146,973
2024-01-04 Malik Fady Ibraham EVP Research & Development Exercise or conversion · Incentive Stock Option (Right to Buy) 10b5-1 −11,678 0
2024-01-02 Wysenski Nancy Director Grant or award +74 $84.12 $6K 17,156
2024-01-02 WIERENGA WENDALL Director Grant or award +74 $84.12 $6K 18,727
2024-01-02 SMITH SANDFORD D Director Grant or award +148 $84.12 $12K 18,801
2024-01-02 Kaye Edward M. MD Director Grant or award +148 $84.12 $12K 19,317
2024-01-02 HENDERSON JOHN T Director Grant or award +252 $84.12 $21K 42,632
2024-01-02 Harrington Robert Arthur Director Grant or award +148 $84.12 $12K 11,521

Page 36 of 45 · 885 trades